Cargando…

Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL

Functional tumor volume (FTV) measurements by dynamic contrast-enhanced magnetic resonance imaging can predict treatment outcomes for women receiving neoadjuvant chemotherapy for breast cancer. Here, we explore whether the contrast thresholds used to define FTV could be adjusted by breast cancer sub...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Wen, Arasu, Vignesh, Newitt, David C., Jones, Ella F., Wilmes, Lisa, Gibbs, Jessica, Kornak, John, Joe, Bonnie N., Esserman, Laura J., Hylton, Nola M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Grapho Publications, LLC 2016
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5214452/ https://www.ncbi.nlm.nih.gov/pubmed/28066808 http://dx.doi.org/10.18383/j.tom.2016.00247

Ejemplares similares

Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL
por: Olshen, Adam, et al.
Publicado: (2017)

Expert tumor annotations and radiomics for locally advanced breast cancer in DCE-MRI for ACRIN 6657/I-SPY1
por: Chitalia, Rhea, et al.
Publicado: (2022)

Impact of MRI Protocol Adherence on Prediction of Pathological Complete Response in the I-SPY 2 Neoadjuvant Breast Cancer Trial
por: Onishi, Natsuko, et al.
Publicado: (2020)

Clinically Meaningful Tumor Reduction Rates Vary by Prechemotherapy MRI Phenotype and Tumor Subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
por: Mukhtar, Rita A., et al.
Publicado: (2013)

Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I-SPY trial (CALGB 150007/150015/ACRIN6657)
por: Clark, Amy S, et al.
Publicado: (2014)

Impact of deformable registration methods for prediction of recurrence free survival response to neoadjuvant chemotherapy in breast cancer: Results from the ISPY 1/ACRIN 6657 trial
por: Thakran, Snekha, et al.
Publicado: (2022)

Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes
por: Lo, Wei-Ching, et al.
Publicado: (2016)

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
por: Esserman, Laura J., et al.
Publicado: (2011)

Tumor Sphericity Predicts Response in Neoadjuvant Chemotherapy for Invasive Breast Cancer
por: Li, Wen, et al.
Publicado: (2020)

Comparison of Segmentation Methods in Assessing Background Parenchymal Enhancement as a Biomarker for Response to Neoadjuvant Therapy
por: Nguyen, Alex Anh-Tu, et al.
Publicado: (2020)

MRI Enhancement in Stromal Tissue Surrounding Breast Tumors: Association with Recurrence Free Survival following Neoadjuvant Chemotherapy
por: Jones, Ella F., et al.
Publicado: (2013)

Retrospective Correction of ADC for Gradient Nonlinearity Errors in Multicenter Breast DWI Trials: ACRIN6698 Multiplatform Feasibility Study
por: Malyarenko, Dariya I., et al.
Publicado: (2020)

Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy
por: Li, Wen, et al.
Publicado: (2022)

Repeatability and Reproducibility of ADC Histogram Metrics from the ACRIN 6698 Breast Cancer Therapy Response Trial
por: Newitt, David C., et al.
Publicado: (2020)

Effect of Inter-Reader Variability on Diffusion-Weighted MRI Apparent Diffusion Coefficient Measurements and Prediction of Pathologic Complete Response for Breast Cancer
por: Le, Nu N., et al.
Publicado: (2022)

Diffusion Tensor Imaging for Assessment of Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer
por: Wilmes, Lisa J., et al.
Publicado: (2016)

Impact of Alternate b-Value Combinations and Metrics on the Predictive Performance and Repeatability of Diffusion-Weighted MRI in Breast Cancer Treatment: Results from the ECOG-ACRIN A6698 Trial
por: Partridge, Savannah C., et al.
Publicado: (2022)

Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL
por: Li, Wen, et al.
Publicado: (2020)

Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosis
por: Huang, Shih-ying, et al.
Publicado: (2018)

Evaluation of primary breast cancers using dedicated breast PET and whole-body PET
por: Hathi, Deep K., et al.
Publicado: (2020)

Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy
por: Jones, Ella F., et al.
Publicado: (2020)

Post-Processing Bias Field Inhomogeneity Correction for Assessing Background Parenchymal Enhancement on Breast MRI as a Quantitative Marker of Treatment Response
por: Nguyen, Alex Anh-Tu, et al.
Publicado: (2022)

Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk
por: Magbanua, Mark Jesus M., et al.
Publicado: (2021)

Radiomic tumor phenotypes augment molecular profiling in predicting recurrence free survival after breast neoadjuvant chemotherapy
por: Chitalia, Rhea, et al.
Publicado: (2023)

Prediction of Treatment Response to Neoadjuvant Chemotherapy for Breast Cancer via Early Changes in Tumor Heterogeneity Captured by DCE-MRI Registration
por: Jahani, Nariman, et al.
Publicado: (2019)

Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma
por: Abel, Mary Kathryn, et al.
Publicado: (2021)

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2(+) breast cancer in the adaptively randomized I-SPY2 trial
por: Clark, Amy S., et al.
Publicado: (2021)

Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial
por: Parker, Barbara A., et al.
Publicado: (2023)

DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial
por: Wolf, Denise M., et al.
Publicado: (2017)

Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol
por: Jones, Ella F., et al.
Publicado: (2019)

SpiNNTools: The Execution Engine for the SpiNNaker Platform
por: Rowley, Andrew G. D., et al.
Publicado: (2019)

Spy&Go purification of SpyTag-proteins using pseudo-SpyCatcher to access an oligomerization toolbox
por: Khairil Anuar, Irsyad N. A., et al.
Publicado: (2019)

Spying on the environment.
Publicado: (1995)

The virus spy
por: Hoag, Hannah
Publicado: (2009)

Catching a SPY: Using the SpyCatcher-SpyTag and Related Systems for Labeling and Localizing Bacterial Proteins
por: Hatlem, Daniel, et al.
Publicado: (2019)

SpyDisplay: A versatile phage display selection system using SpyTag/SpyCatcher technology
por: Kellmann, Sarah-Jane, et al.
Publicado: (2023)

Agreement of Mammographic Measures of Volumetric Breast Density to MRI
por: Wang, Jeff, et al.
Publicado: (2013)

Development of SpyTag/SpyCatcher-Bacmid Expression Vector System (SpyBEVS) for Protein Bioconjugations Inside of Silkworms
por: Xu, Jian, et al.
Publicado: (2019)

SpyTag/SpyCatcher Cyclization Enhances the Thermostability of Firefly Luciferase
por: Si, Meng, et al.
Publicado: (2016)

The spy that went into the cold
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_vuq5bvi976p6uv0kn01cmf5tg0